Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.

Trial Details

NCT ID
NCT07168980
Phase
PHASE2 / PHASE3
Sponsor
Children's Cancer Group, China
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
  • Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
  • Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
  • Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
  • Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone
  • Prednisone,Vincristine, Cyclophosphamide
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
  • Able to comply with scheduled follow-up and with management of toxicity
  • Signed informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →